Related Experiment Videos
Effects of eprosartan on glomerular injury in rats with reduced renal mass
M Gandhi1, T W Meyer, D P Brooks
1Department of Medicine, Palo Alto VA Health Care System and Stanford University, Palo Alto, Calif., USA.
Abstract:
The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.
Insights
Eprosartan, an angiotensin AT1 receptor antagonist, effectively treated experimental renal disease in rats. It normalized blood pressure, reduced proteinuria, and limited glomerulosclerosis, suggesting its potential for treating progressive kidney disease.
Area of Science:
- Nephrology
- Pharmacology
- Cardiovascular Research
Background:
- Experimental renal disease models are crucial for understanding kidney disease progression.
- Hypertension, proteinuria, and glomerulosclerosis are key indicators of renal damage.
- Angiotensin II plays a significant role in the pathophysiology of renal disease.
Purpose of the Study:
- To evaluate the efficacy of eprosartan, a selective angiotensin AT1 receptor antagonist, in a rat model of experimental renal disease.
- To assess the impact of eprosartan on blood pressure, proteinuria, and glomerulosclerosis.
- To determine if eprosartan can mitigate the progression of renal damage.
Main Methods:
- Induction of five-sixth nephrectomy in male Munich-Wistar rats to create experimental renal disease.
- Administration of eprosartan (AT1 receptor antagonist) or vehicle for 4 weeks.
- Measurement of blood pressure, proteinuria, and histological assessment of remnant glomerulosclerosis.
- Confirmation of angiotensin II activity inhibition via blood pressure response to exogenous angiotensin II.
Main Results:
- Eprosartan treatment significantly inhibited angiotensin II activity.
- Compared to vehicle, eprosartan normalized blood pressure in the rats.
- Eprosartan administration led to a marked reduction in proteinuria.
- Histological analysis showed that eprosartan limited the development of remnant glomerulosclerosis.
Conclusions:
- Eprosartan effectively ameliorates hypertension, proteinuria, and glomerulosclerosis in experimental renal disease.
- The findings suggest that targeting the angiotensin AT1 receptor with eprosartan is a viable therapeutic strategy.
- Eprosartan shows promise as a novel therapeutic agent for managing progressive renal diseases.